Despite approved therapies for chronic kidney disease (CKD), many patients experience progressive loss of kidney function, and there remains an unmet need for additional therapies. Hierarchical composite endpoints (HCEs) have emerged as candidate tools to improve the efficiency of randomized controlled trials (RCTs) by integrating multiple outcomes ranked by clinical importance. The National Kidney Foundation convened a Scientific Workshop involving a broad group of stakeholders to consider the application of HCEs to CKD.